As Flagship shrinks Moderna holdings, Fidelity bulks up

One of the shareholders dramatically increased its Moderna stake as the Cambridge biotech developed a Covid-19 vaccine and its stock price skyrocketed. The other shrank its stake by more than a fifth over the same time period.